STANDARD OF CARE TEMOZOLOMIDE CHEMOTHERAPY ± TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA. FINAL RESULTS OF THE PHASE III EF-14 CLINICAL TRIAL

被引：0
|
作者：
Stupp, R. [1 ,2 ]
Ram, Z. [3 ]
机构：
[1] Univ Zurich, Zurich, Switzerland
[2] EF 14 Investigators, Zurich, Switzerland
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
来源：
NEURO-ONCOLOGY | 2017年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OS07.9
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [1] EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA. RESULTS OF THE EF-14 RANDOMIZED PHASE III TRIAL
    Taphoorn, Martin J. B.
    Dirven, Linda
    Taillibert, Sophie
    Honnorat, Jerome
    Chen, Thomas
    Sroubek, Jan
    Paek, Sun-Ha
    Escuder, Jordi Bruna
    Easaw, Jacob C.
    David, Carlos A.
    Kim, Chae-Yong
    Desai, Rajiv D.
    Kew, Yvonne
    Olivi, Alessandro
    Nicholas, Garth A.
    Lavy-Shahaf, Gitit
    Kirson, Eilon D.
    Ram, Zvi
    Stupp, Roger
    NEURO-ONCOLOGY, 2017, 19 : 206 - 206
  • [2] Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields with Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.
    Choe, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S48 - S48
  • [3] Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
    Ram, Zvi
    Kim, Chae-Yong
    Hottinger, Andreas F.
    Idbaih, Ahmed
    Nicholas, Garth
    Zhu, Jay-Jiguang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Phase III TRIDENT trial: Radiation and temozolomide plus /- tumor treating fields in newly diagnosed glioblastoma.
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel Aaron
    Nagpal, Seema
    Reardon, David A.
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Glas, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Efficacy of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase III EF-14 trial.
    Ram, Zvi
    Kim, Chae-Yong
    Zhu, Jay-Jiguang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] COMPLIANCE AND TREATMENT DURATION PREDICT SURVIVAL IN A PHASE 3 EF-14 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Ram, Zvi
    Kim, Chae-Yong
    Nicholas, Garth A.
    Toms, Steven
    NEURO-ONCOLOGY, 2017, 19 : 6 - 7
  • [7] Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
    Chae-Yong Kim
    Sun Ha Paek
    Do-hyun Nam
    Jong-Hee Chang
    Yong-Kil Hong
    Jeong Hoon Kim
    Oh Lyong Kim
    Se-Hyuk Kim
    Journal of Neuro-Oncology, 2020, 146 : 399 - 406
  • [8] Effects of Tumor Treating Fields (TTFields) on Health-Related Quality of Life (HRQOL) in Newly Diagnosed Glioblastoma: An Exploratory Analysis of the EF-14 Randomized Phase III Trial
    Toms, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S170 - S171
  • [9] Increasing Tumor Treating Fields dose at the tumor bed improves survival: Setting a framework for TTFields dosimetry based on analysis of the EF-14 Phase III trial in newly diagnosed glioblastoma
    Ballo, Matthew T.
    Urman, Noa
    Bomzon, Ze'ev
    Lavy-Shahaf, Gitit
    Toms, Steven
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
    Kim, Chae-Yong
    Paek, Sun Ha
    Nam, Do-hyun
    Chang, Jong-Hee
    Hong, Yong-Kil
    Kim, Jeong Hoon
    Kim, Oh Lyong
    Kim, Se-Hyuk
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (03) : 399 - 406
12345